Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers

BACKGROUND: P276-00 is a novel cyclin-dependent kinase inhibitor currently in Phase II clinical trials. Gemcitabine is a standard of care for the treatment of pancreatic cancer. The present study investigated the effect of the combination of P276-00 and gemcitabine in five pancreatic cancer cell lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathos, Maggie J, Joshi, Kavita, Khanwalkar, Harshal, Manohar, Sonal M, Joshi, Kalpana S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478973/
https://www.ncbi.nlm.nih.gov/pubmed/22873289
http://dx.doi.org/10.1186/1479-5876-10-161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478973/
https://www.ncbi.nlm.nih.gov/pubmed/22873289
http://dx.doi.org/10.1186/1479-5876-10-161

Ejemplares similares